“Taking 250 mg of purified Shilajit twice daily for 8 weeks increased the activity of 17 muscle-related gene markers involved in muscle structure, elasticity, repair, and regeneration, according to a study published in the Journal of Medicinal Food (PMID: 27414521)”
Plain restatementA study in the Journal of Medicinal Food reported that 250 mg of a purified shilajit extract taken twice daily for 8 weeks was associated with increased expression of 17 extracellular-matrix-related gene probe sets in human skeletal muscle.
The study cited in this ad is real and the post describes it fairly accurately. Researchers gave 16 overweight or obese adults 250 mg of a purified shilajit extract twice daily for 8 weeks, took muscle biopsies, and found 17 extracellular-matrix-related gene readings had increased compared to each person's own starting point, including collagen, elastin, fibrillin, fibronectin, decorin, and myoferlin. What the ad leaves out is important. The study had no placebo group and no control group, only 16 people, and it was partly funded by the company that makes the specific branded extract that was tested, which is not the product being advertised. It also measured only gene activity, not muscle growth, strength, or recovery, so the muscle growth and performance framing goes beyond what was actually tested. Treat this as an early mechanistic signal from a small uncontrolled study, not as proof that shilajit builds or repairs muscle.
[drifted from the evidence:] Taking 250 mg of purified Shilajit twice daily for 8 weeks increased [drifted from the evidence:] the activity of 17 [drifted from the evidence:] muscle-related gene [drifted from the evidence:] markers involved in muscle [drifted from the evidence:] structure, elasticity, repair, and regeneration, according to a study published in the Journal of Medicinal Food (PMID: 27414521)
[added by the neutral restatement:] A study in the Journal of Medicinal Food reported that 250 mg of [added by the neutral restatement:] a purified shilajit [added by the neutral restatement:] extract taken twice daily for 8 weeks [added by the neutral restatement:] was associated with increased [added by the neutral restatement:] expression of 17 [added by the neutral restatement:] extracellular-matrix-related gene [added by the neutral restatement:] probe sets in [added by the neutral restatement:] human skeletal muscle.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The study exists, PMID 27414521 and PMCID PMC4948208 are correct, and it was published in the Journal of Medicinal Food.
- The dose and duration are accurately stated: 250 mg twice daily for 8 weeks.
- The number 17 is accurate as published, referring to 17 ECM-related probe sets significantly upregulated versus baseline.
- The listed gene families (collagen, elastin, fibrillin, fibronectin, decorin, myoferlin) are accurately reported.
- The descriptors "mechanotransduction, elasticity, repair, and regeneration" are essentially the authors' own wording, not an embellishment.
- The stated conclusion, that shilajit promoted molecular changes associated with skeletal muscle adaptation, matches the paper's conclusion.
- This was human research, not animal or cell-culture work.
- Omitted qualifier (study design): the post calls it "a clinical trial" without disclosing that it was open-label and single-arm with no placebo or control group. Changes from baseline in an uncontrolled study cannot be cleanly attributed to the supplement.
- Omitted qualifier (sample size and population): n = 16, all overweight or class I obese adults. The post says "adults," implying general applicability.
- Omitted qualifier (funding and product specificity): the tested material was Natreon's patented, standardized PrimaVie extract, and Natreon partially funded the work. The ad uses this to sell a different company's product. Results from one standardized extract do not automatically transfer to another brand's shilajit.
- Surrogate endpoint presented as outcome: the study measured gene expression, not muscle growth, strength, or recovery. The hashtags "#musclegrowth #recovery #performance" imply functional benefits the 8-week data did not test.
- Precision drift: "17 gene targets" or "17 muscle-related gene markers" is a reasonable shorthand, but the published unit is 17 microarray probe sets out of 175 differentially regulated probe sets. Probe sets are not strictly equivalent to 17 distinct genes.
- Selective presentation: the same 8-week data showed no change in creatine kinase or myoglobin, and the study's exercise component was a separate later phase. The ad presents only the favorable molecular signal.
- Whether upregulation of these ECM transcripts produces any measurable real-world change in muscle mass, strength, or injury resistance. The study did not test this.
- Whether the finding replicates. Only one small uncontrolled study of this design was found. A separate randomized placebo-controlled trial in 63 recreationally active men reported that 8 weeks of PrimaVie Shilajit at 500 mg per day promoted retention of maximal muscular strength following a fatiguing protocol and decreased baseline hydroxyproline , but that is a different study with different endpoints and does not verify the gene-expression claim.
- How much of the observed change reflects the supplement versus time, diet, seasonal variation, or biopsy-site and batch effects, which an uncontrolled design cannot separate.
- Whether the advertiser's own shilajit product matches the tested extract in fulvic acid content, dibenzo-alpha-pyrone content, or purity. No evidence on that was found.
The cited study is real and the identifiers check out. The study design consisted of a baseline visit, followed by 8 weeks of 250 mg of oral Shilajit supplementation twice daily, and an additional 4 weeks of supplementation with exercise, with blood samples and muscle biopsies collected at each visit. Microarray analysis identified a cluster of 17 extracellular matrix (ECM)-related probe sets that were significantly upregulated in muscles following 8 weeks of oral supplementation compared with the expression at baseline. This cluster included tenascin XB, decorin, myoferlin, collagen, elastin, fibrillin 1, and fibronectin 1. The authors framed this as evidence that supplementation promoted skeletal muscle adaptation through upregulation of ECM-related genes that control muscle mechanotransduction properties, elasticity, repair, and regeneration . So the post's numbers, dose, duration, gene list, and conclusion language all track the published abstract closely.
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/7226bfe36189/EoVsTmuASty25uEyAeTjZDp
Ask this case
Answers come only from the case file above; nothing is added.
Is the study behind this claim real?
Yes. It was published in the Journal of Medicinal Food in 2016 (PMID 27414521), and the dose, duration, and gene findings described in the post match the published study closely.
Does this mean shilajit builds muscle or improves recovery?
No. The study only measured gene expression in muscle biopsies, not actual muscle growth, strength, or recovery. Framing like #musclegrowth or #performance goes beyond what the 8-week data tested.
How strong is this evidence?
It is limited. The study had only 16 participants, all overweight or obese adults, and there was no placebo or control group, so changes cannot be cleanly attributed to the supplement alone.
Does the funding or product tested affect how this claim should be read?
Yes. The study tested a specific patented extract called PrimaVie, made by Natreon, which partially funded the research. This is a different product from the one being advertised, so results may not transfer directly.
Has this finding been confirmed by other research?
The investigation found only one study of this kind. A separate randomized trial looked at shilajit and muscular strength but used different methods and endpoints, so it does not confirm the gene-expression results described here.